Diferencia entre revisiones de «Valganciclovir»

Revisión actual - 02:38 20 mar 2026

Disease	Dose	Context
CMV retinitis	900mg PO q12hrs x 14 days then 900mg PO q24hrs x 7 days	Severe vision threatening with intraocular implant
CMV retinitis	900mg PO q12hrs x 21 days then 900mg PO q24hrs x 7 days	Peripheral lesions

Neonatal CMV infection: 17 mg/kg PO daily BID x 12 weeks, then 17 mg/kg daily until 1 year of age

Pregnancy Rating: Category C, fetal risk cannot be ruled out
Lactation risk: infant risk cannot be ruled out
Renal dosing
- CrCl 40-59 mL/min: 450 mg BID
- CrCl 25-39 mL/min: 450 mg once daily
- CrCl 10-24 mL/min: 450 mg every 2 days
- CrCl < 10 mL/min or on HD: not recommended
Hepatic dosing:

Authors:

@@ Línea 8: / Línea 8: @@
 *CMV infection: 900 mg PO BID
 *CMV prophylaxis: 900 mg PO daily
+===Indications by Disease===
+{{#ask: [[Has DrugName::Valganciclovir]] [[Has Population::Adult]]
+ |?Treats disease=Disease
+ |?Has Dose=Dose
+ |?Has Context=Context
+ |format=table
+ |limit=50
+ |mainlabel=-
+ |headers=show
+ |sort=Treats disease
+}}
 ==Pediatric Dosing==
 *Neonatal CMV infection: 17 mg/kg PO daily BID x 12 weeks, then 17 mg/kg daily until 1 year of age
+===Indications by Disease===
+{{#ask: [[Has DrugName::Valganciclovir]] [[Has Population::Pediatric]]
+ |?Treats disease=Disease
+ |?Has Dose=Dose
+ |?Has Context=Context
+ |format=table
+ |limit=50
+ |mainlabel=-
+ |headers=show
+ |sort=Treats disease
+}}
 ==Special Populations==